Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum β-lactamases in community- and hospital-associated intra-abdominal infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 3043-3046

  Hawser, Stephen P ^a   Bouchillon, Samuel K ^b   Hoban, Daryl J ^b   Badal, Robert E ^b   Cantón, Rafael ^c,d   Baquero, Fernando ^c,d  

^a International Health Management Associates Europe Sàrl   (Switzerland)

^b Division of Microbiology   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; SULTAMICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMMUNITY ASSOCIATED INFECTION; CONTROLLED STUDY; DRUG MONITORING; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EUROPE; HOSPITAL INFECTION; INCIDENCE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ABDOMEN; CROSS INFECTION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; HUMAN; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIOLOGY;

ABDOMEN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE;

EID: 77953769710     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00265-10     Document Type: Article

References (27)

1. Baquero, F., P. R. Hsueh, D. L. Paterson, F. Rossi, G. V. Bochicchio, G. Gallaghe, K. Lantz, J. B. Villasenor, K. McCarroll, M. A. Abramson, and J. W. Chow. 2009. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg. Infect. 10:99-104.
2. Ben-Ami, R., J. Rodriguez-Bano, H. Arsian, J. D. Pitout, C. Quentin, E. S. Calbo, O. K. Azap, C. Arpin, A. Pascual, D. M. Livermore, J. Garau, and Y. Carmeli. 2009. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690.
3. Bochicchio, G. V., F. Baquero, P. R. Hsueh, D. L. Paterson, F. Rossi, T. A. Snyder, K. McCarroll, V. Satishchandran, M. J. Dinubile, and J. W. Chow. 2006. In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg. Infect. 7:537-545.
4. Canton, R., A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, and T. M. Coque. 2008. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 14(Suppl. 1):144-153.
5. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. CLSI M100-S18. Clinical Laboratory Standards Institute, Wayne, PA.
7. Coque, T. M., F. Baquero, and R. Canton. 2008. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 13:19044.
8. Doshi, R. K., G. Patel, R. Mackay, and F. Wallach. 2009. Hospital-acquired infections: epidemiology, prevention, and therapy. Mt. Sinai J. Med. 76:84-94.
9. Goossens, H., and B. Grabein. 2005. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn. Microbiol. Infect. Dis. 53:257-264.
10. Gulmez, D., N. Woodford, M. F. Palepou, S. Mushtaq, G. Metan, Y. Yakupogullari, S. Kocagoz, O. Uzun, G. Hascelik, and D. M. Livermore. 2008. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int. J. Antimicrob. Agents 31:523-526.
11. Hawser, S. P., S. K. Bouchillon, D. J. Hoban, R. E. Badal, P-R. Hsueh, and D. L. Paterson. 2009. Emergence of high levels of extended-spectrum-β- lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. Antimicrob. Agents Chemother. 53:3280-3284.
12. Reference deleted.
13. Hirakata, Y., J. Matsuda, Y. Miyazaki, S. Kamihira, S. Kawakami, Y. Miyazawa, Y. Ono, N. Nakazaki, Y. Hirata, and M. Inoue. 2005. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn. Microbiol. Infect. Dis. 52:323-329.
14. Reference deleted.
15. Leavitt, A., I. Chmelnitsky, R. Colodner, I. Ofek, Y. Carmeli, and S. Navon-Venezia. 2009. Ertapenem resistance among extended-spectrum-beta- lactamase-producing Klebsiella pneumoniae isolates. J. Clin. Microbiol. 47:969-974.
16. Liu, C. Y., C. L. Lu, Y. T. Huang, C. H. Liao, and P-R. Hsueh. 8 September 2009. In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intra-abdominal infections at a medical center in Taiwan, 2001-2006. Eur. J. Clin. Microbiol. Infect. Dis. [Epub ahead of print.] doi:10.1007/s10096-009-0801-x.
17. Livermore, D. M., R. Hope, H. Brick, M. Lillie, R. Reynolds, and the BSAC Working Parties on Resistance Surveillance. 2008. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 62(Suppl. 2):ii41-ii54.
18. Livermore, D. M., R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, L. Poirel, and N. Woodford. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59:165-174.
19. Lockhart, S. R., M. A. Abramson, S. E. Beekmann, G. Gallagher, S. Riedel, D. J. Diekema, J. P. Quinn, and G. V. Doern. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care units in the United States between 1993 and 2004. J. Clin. Microbiol. 45:3352-3359. (Pubitemid 47585661)
20. Mazuski, J. E., and J. S. Solomkin. 2009. Intra-abdominal infections. Surg. Clin. North. Am. 89:421-437.
21. Pitout, J. D., P. Nordmann, K. B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56:52-59.
22. Rossi, F., F. Baquero, P.-R. Hsueh, D. L. Paterson, G. V. Bochicchio, T. A. Snyder, V. Satishchandran, K. McCarroll, M. J. DiNubile, and J. W. Chow. 2006. In vitro susceptibilities of aerobic and facultatively anaerobic Gramnegative bacilli from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58:205-210.
23. Sader, H. S., A. Hsiung, T. R. Fritsche, and R. N. Jones. 2007. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn. Microbiol. Infect. Dis. 57:341-344.
24. Valverde, A., T. M. Coque, and M. P. Sánchez-Moreno. 2004. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during non-outbreak situations in Spain. J. Clin. Microbiol. 42:4769-4775.
25. Vinue, L., Y. Saenz, S. Martinez, S. Somalo, M. A. Moreno, C. Torres, and M. Zarazaga. 9 June 2009. Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin. Microbiol. Infect. [Epub ahead of print.] doi:10.1111/j.1469-0691. 2009.02803.x.
26. Woodford, N., J. W. Dallow, R. L. Hill, M. F. Palepou, R. Pike, M. E. Ward, M. Warner, and D. M. Livermore. 2007. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int. J. Antimicrob. Agents 29:456-459.
27. Woodford, N., J. Zhang, M. Warner, M. E. Kaufmann, J. Matos, A. Macdonald, D. Brudney, D. Sompolinsky, S. Navon-Venezia, and D. M. Livermore. 2008. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J. Antimicrob. Chemother. 62:1261-1264.